182 related articles for article (PubMed ID: 33132262)
21. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
[TBL] [Abstract][Full Text] [Related]
22. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
[TBL] [Abstract][Full Text] [Related]
23. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Okui D; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
[TBL] [Abstract][Full Text] [Related]
24. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
Furihata K; Nagasawa K; Hagino A; Kumagai Y
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):36-43. PubMed ID: 32076889
[TBL] [Abstract][Full Text] [Related]
25. Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.
Taniguchi T; Omura K; Motoki K; Sakai M; Chikamatsu N; Ashizawa N; Takada T; Iwanaga T
Sci Rep; 2021 Mar; 11(1):7232. PubMed ID: 33790363
[TBL] [Abstract][Full Text] [Related]
26. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Iqbal A; Iqbal K; Farid E; Ishaque A; Hasanain M; Bin Arif T; Arshad Ali S; Rathore SS; Malik M
Cureus; 2021 Apr; 13(4):e14428. PubMed ID: 33996294
[TBL] [Abstract][Full Text] [Related]
28. Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
Takahashi T; Sasaki M; Shimizu T; Yamaguchi S
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):87-95. PubMed ID: 37559414
[TBL] [Abstract][Full Text] [Related]
29. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M; Adachi H
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
[TBL] [Abstract][Full Text] [Related]
30. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
Motoki K; Igarashi T; Omura K; Nakatani H; Iwanaga T; Tamai I; Ohashi T
Pharmacol Res Perspect; 2019 Dec; 7(6):e00533. PubMed ID: 31788318
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
[TBL] [Abstract][Full Text] [Related]
33. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
Nakatani H; Fushimi M; Sasaki T; Okui D; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):8-16. PubMed ID: 31889230
[TBL] [Abstract][Full Text] [Related]
35. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
[TBL] [Abstract][Full Text] [Related]
37. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
Amano H; Kobayashi S; Terawaki H
BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
[TBL] [Abstract][Full Text] [Related]
38. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Mar; 60(3):159-166. PubMed ID: 34779393
[TBL] [Abstract][Full Text] [Related]
40. Uricosuric targets of tranilast.
Mandal AK; Mercado A; Foster A; Zandi-Nejad K; Mount DB
Pharmacol Res Perspect; 2017 Apr; 5(2):e00291. PubMed ID: 28357121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
